

TO-THE-POINT

A Vaccine Provider Newsletter from the Barry-Eaton District Health Department

NEW PFIZER COVID-19 PRESENTATION

On December 18th, 2023 the CDC replaced the previous VFC Pfizer 12y+ vaccine allocation with Pfizer's new **refrigerated** 12y+ vaccine (NDC 00069-2377-10), a new presentation in a carton of 10 manufacturer-filled syringes (MFS). The newest version of the 12y+ Pfizer will have the same CVX. The **old** NDC was COMIRNATY 12 PLUS VIAL, the **new** NDC is <u>COMIRNATY 12 PLUS SYRINGE</u> <u>REFRIGERATED</u>.

 This new presentation MUST BE STORED BETWEEN 2°C and 8°C (36°F and 46°F).

Do NOT store at ultra-cold or standard freezer temperatures.

 This new vaccine comes in a carton which has a bright pink stripe that includes the words
"DO NOT FREEZE" to alert the provider about the storage and handling requirements.

NDC 006	9-2377-10
COVID-19 Vaccine, mRNA	
2023 – 2024 Formula	
Suspension for Intramuscular Injection	
10 Single Dose Prefilled Syringes	
Each prefilled syringe contains 1 dose of 0.3 mL	
For 12 years of age and older	
DO NOT FREEZE	
BIONTECH OPPar	Rx only

- These manufacturer-filled syringes can be used through the expiration date printed on the carton. The 10-week beyond-use date (BUD) for refrigerator storage does not apply.
- This guidance applies to this presentation ONLY. Pfizer-BioNTech COVID-19 vaccines for children aged 6m-4y and 5-11y, which are shipped to providers under CDC's VFC program directly from Pfizer on dry ice, can be stored at ultracold temperatures until expiry or up to 10 weeks at 2-8C.
- Providers who have the original Pfizer 12y+ vaccine on hand can and should continue to use this product until it is administered, expired, or has been stored at 2-8C for longer than the allowable 10 weeks.

POLIO RECOMMENDATIONS

Previously, inactivated polio vaccine (IPV) recommendations for U.S. adults addressed adults known to be at risk for poliovirus exposure, however, on June 21, 2023, the Advisory Committee on Immunization Practices (ACIP) issued an Inactivated Polio Vaccine (IPV) recommendation for all adults known or suspected to be unvaccinated or incompletely vaccinated against polio. Risk-based recommendations for IPV boosters have not changed.

On December 8, 2023, the Centers for Disease Control and Prevention (CDC) published a Morbidity and Mortality Weekly Report (MMWR) titled <u>Use of Inactivated Polio Vaccine Among</u> <u>U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices —</u> <u>United States, 2023</u>. This report contains recommendations for adults aged 18 years and older who are known or suspected to be unvaccinated or incompletely vaccinated against polio to complete a primary polio vaccination series with IPV. Fully vaccinated adults at increased risk for poliovirus exposure may receive a single lifetime booster dose of IPV.

RSV VACCINATION PRODUCTS

<text><text><text><section-header><section-header><section-header></section-header></section-header></section-header></text></text></text>	A CONTRACTOR OF	
Abrysvo	Arexvy	Beyfortus (nirsevimab)
Manufactured by Pfizer	Manufactured by GSK	Distributed by Sanofi and manufactured by AstraZeneca
ADULT RSV product	ADULT RSV product	For use in Infants and Children
For use in adults 60 years and older as a shared clinical decision-making conversation between patients and providers	For use in adults 60 years and older as a shared clinical decision-making conversation between patients and providers	NOT TO BE USED FOR ADULTS
For use in pregnant people 32 through 36 weeks pregnant during the RSV season of September through January to help prevent RSV in newborns Abrysvo is currently the only U.S. licensed RSV vaccine for pregnant people	NOT TO BE USED FOR PREGNANT PEOPLE	NOT TO BE USED FOR
NOT TO BE USED FOR INFANTS/CHILDREN	NOT TO BE USED FOR INFANTS/CHILDREN	FOR USE IN INFANTS AND CHILDREN during the RSV season of September through April.

Suggestions for Preventing Administration Errors:

- If more than one RSV product is carried, keep them in separate areas of a storage unit
- Prominently label the different products and dose volumes (maybe use a different color of signage)
- Put age indications on the labels of these products in a storage unit
- Triple check the vaccine being given to make sure it is the correct vaccine for the patient
- Know the vaccines and who they are recommended for (e.g., age groups, medical status)

RESOURCES

- <u>Child and Adolescent Recommended Immunization Schedule, 2024</u>
- Adult Recommended Immunization Schedule, 2024